Navigation Links
Research shows treating HIV-AIDS with interleukin-2 is ineffective
Date:10/15/2009

This release is available in French.

An international research team has demonstrated that treating HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the researchers recommend that clinical trials on this compound be stopped. Their finding was published in the New England Journal of Medicine in an article co-authored by 14 researchers, including Dr. Jean-Pierre Routy of the Research Institute of the McGill University Health Centre (RI-MUHC).

IL-2 is currently used as a complement to highly active antiretroviral therapy (known as HAART), which is administered to patients with HIV-AIDS. Since HAART controls replication of viruses in the blood, doctors thought that IL-2 would help regenerate more CD4+ immune cells, which serve as an indicator of viral progression. It was thought that IL-2 increased the natural immunity of patients by helping immune cells mature and multiply.

"Our results show that IL-2 has no effect on the development of AIDS or on patient survival," says Dr. Routy. "More precisely, while the presence of IL-2 leads to a faster increase of CD4+ immune cells, these cells are less functional than the CD4+ cells that regenerate naturally in patients who do not receive IL-2. This means that IL-2 treatment provides no benefit and does not prevent AIDS-related infectious diseases."

"For the first time, a study has shed light on recurring questions concerning the value of biological markers and their limitations in assessing patient health," explains Dr. Routy. "Our challenge now will be to develop tests that assess the function of immune cells and not simply their quantity. This will ensure that HIV treatments indeed have a clinical benefit for patients."

This 8-year study involved over 5000 patients in 25 countries, and was one of the largest ever conducted on HIV-AIDS. "The fact that data from developing countries was used in biomedical research on innovative compounds is very revolutionary in the history of HIV-AIDS research," explains Dr. Routy.


'/>"/>

Contact: Julie Robert
julie.robert@muhc.mcgill.ca
514-843-1560
McGill University Health Centre
Source:Eurekalert

Related biology news :

1. Research shows skeleton to be endocrine organ
2. Newly created cancer stem cells could aid breast cancer research
3. Dominant cholesterol-metabolism ideas challenged by new research
4. Researchers identify proteins involved in new neurodegenerative syndrome
5. Texas researchers and educators head for Antarctica
6. MGH researchers describe new way to identify, evolve novel enzymes
7. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
8. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
9. U of MN researchers discover noninvasive diagnostic tool for brain diseases
10. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
11. Story ideas from the Journal of Lipid Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
(Date:1/6/2017)...  SomaLogic announced today that it has agreed ... iCarbonX, the China -based company ... Health Ecosystem that can define each person,s ,digital ... behavioral and psychological data, the Internet and artificial ... will provide proteomics data and applications expertise to ...
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017 /PRNewswire/ ... in performance biometric sensor technology, today announced the ... Benchmark™ sensor systems, the highly-accurate biometric sensor ... ® biometric technology, experience and expertise. The ... of Benchmark designed specifically for hearables, and Benchmark ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... 2017 , ... BidMed, LLC, announced it will hold a 1-day ... equipment from two different leading institutes. This highly specialized laboratory equipment is coming directly ... This 1-day online auction will take place on BidMed’s website http://www.bidmed.com ...
(Date:1/18/2017)... Jan. 18, 2017 Shareholder rights law firm ... whether the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... connection with the proposed sale of the Company to ... that develops small molecules for the acute treatment of ... it had signed a definitive merger agreement with Eli ...
(Date:1/18/2017)... 18, 2017 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: ... company that develops and commercializes proprietary technologies and ... "Company"), today announced that Cameron Prange , ... resigned from its Board of Directors.  Mr. Prange,s ... regulations that have limited both his ability to ...
(Date:1/17/2017)... West Point, IA (PRWEB) , ... January 17, ... ... approval from China for Balance™ GT soybeans. The new Balance™ GT Soybean Performance ... tolerance to glyphosate and isoxaflutole, the active ingredient in the new Balance® Bean ...
Breaking Biology Technology: